At 2014 San Antonio Breast Cancer Symposium three new Myriad studies highlighted

[News]

Myriad Genetics, Inc. (NASDAQ: MYGN) has announced results from a new study that demonstrated the ability of the myRisk™ Hereditary Cancer test to detect 105 percent more mutations in cancer...

More... (http://www.medicalnewstoday.com/releases/286760.php)